Colleen Cunningham

Dr Colleen Cunningham’s research examines the challenges and advantages of commercialising new-to-the-world inventions. Dr Cunningham is fascinated by markets for technology, specifically the origins of markets and their role in the selection of novel ideas. Her research also focuses on anti-competitive motivations for technology acquisitions. Her specialism spans high technology innovation and entrepreneurship, focusing in particular on medical technologies such as medical devices and pharmaceuticals. Her research has received awards in health economics, competitive strategy, antitrust, and corporate finance, and has been cited by White House Executive Orders, U.S. Congressional antitrust reports, and EU and UK competition policy. Dr Cunningham was named to the Thinkers50 Radar in 2021.

Prior to academia, Dr Cunningham was a health policy researcher, publishing 12 peer-reviewed articles on health systems management and policy related to pharmaceuticals, and drafting advisory reports for various stakeholders, including health system managers. Dr Cunningham also worked as a consulting researcher for the Economic Development department of the Government of British Columbia (Canada), in the oil and gas industry, and in natural resource management.

Research interests

• Innovation and technology strategy
• Markets for ideas, technology, and firms
• Competition and innovation
• Health innovation and entrepreneurship
• Health care management and policy
• Interfirm relationships

Publications

2021

• Killer acquisitions
  Cunningham C; Ederer F; Ma S
  Journal of Political Economy 2021 Vol 129:3 p 649-702

2019

• Experimenting strategically: Inter-firm relationships and “in-the-field” innovation
  Kapacinskaite A; Cunningham C
  Academy of Management Proceedings 2019 Vol 2019:1

• The limits of relational governance: sales force strategies in the US medical device industry
  Chatterji AK; Cunningham C M; Joseph JE
  Strategic Management Journal 2019 Vol 40:1 p 55-78

2013

• Racial and ethnic disparities in the use of antipsychotic medicatication: a systematic review and meta-analysis
  Puyat J H; Daw J R; Cunningham C M; Law M R; Wong T W; Greyson D L; Morgan S G
  Social Psychiatry and Psychiatric Epidemiology 2013 Vol 48:12 p 1861-1872

2012

• Drug development: innovation or imitation deficit?
  Morgan S G; Cunningham C M; Law M R
  British Medical Journal 2012 Vol 345:e5880

• Information behaviour of Canadian pharmaceutical policy makers
  Greyson D L; Cunningham C M; Morgan S
  Health Information and Libraries Journal 2012 Vol 29:1 p 16-27

2011

• Ethnic differences in the use of prescription drugs: a cross-sectional analysis of linked survey and administrative data
  Morgan S; Hanley G; Cunningham C M; Quan H
  Open Medicine 2011 Vol 5:2 p e87-e92

• Ethnic disparities in antipsychotic drug use in British Columbia: a cross-sectional retrospective study
  Puyat J H; Hanley G E; Cunningham C M; Law M R; Wong S T; Sutherland J M; Morgan S G
  Psychiatric Services 2011 Vol 62:9 p 1026-1031

• Income inequities in end-of-life health care spending in British Columbia, Canada: a cross-sectional analysis, 2004-2006
  Cunningham C M; Hanley G E; Morgan S G
  International Journal for Equity in Health 2011 Vol 10:12

• Population aging and the determinants of healthcare expenditures: the case of hospital, medical and pharmaceutical care in British Columbia, 1996 to 2006
  Morgan S; Cunningham C M
  Healthcare Policy 2011 Vol 7:1 p 68-79

• The cost of drug development: a systematic review
  Morgan S; Grootendorst P; Lexchin J; Cunningham C M; Greyson D
  Health Policy 2011 Vol 100:1 p 4-17

2010

• Individual and contextual determinants of regional variation in prescription drug use: an analysis of administrative data from British Columbia
  Morgan S G; Cunningham C M; Hanley G E
  PLoS ONE 2010

• Listening for prescriptions: a national consultation on pharmaceutical policy issues
  Morgan S; Cunningham C M
  Healthcare Policy 2010 Vol 6:2 p 48-66

• Patterns in the use of benzodiazepines in British Columbia: Examining the impact of increasing research and guideline cautions against long-term use
  Cunningham C M; Hanley G E; Morgan S G
  Health Policy 2010 Vol 97:2-3 p 122-129

2008

• The effect of evidence-based drug coverage policies on pharmaceutical R&D: a case study from British Columbia
  Morgan S; Cunningham C M
  Healthcare Policy 2008 Vol 3:3 p e128-e153

Working papers

2020

• Killer acquisitions
  Cunningham C M; Ederer F; Ma S
  Social Sciences Research Network

2018

• Inventive capabilities in the division of innovative labor
  Arora A; Cohen W M; Cunningham C M
  NBER Working Paper

Books and cases

2009

• The British Columbia medical and hospital atlas : a companion to the British Columbia Rx atlas, 2nd edition
  Morgan S; Cunningham C M; Hanley G; Mooney D
  Centre for Health Services and Policy Research (CHSPR)

• The British Columbia Rx atlas, 2nd edition
  Morgan S; Cunningham C M; Hanley G; Mooney D
  Centre for Health Services and Policy Research (CHSPR)

Awards and Honours

• Sumantra Ghoshal Research and Practice Award, Strategic Management Division, Academy of Management, 2018.
  
• Western Finance Association CRA Corporate Finance Best Paper Award, 2018.
  
• Mark A Satterthwaite Health Care Markets Best Paper Prize, 2018.
  
• Best Dissertation Award (finalist), Strategic Management Division, Academy of Management, 2018.
  
• Kauffman Foundation Dissertation Fellowship, 2017.
  
• Fulbright Canada Student Award, 2011-2012.
  
• Simon Fraser University Graduate Fellowship Award, 2007.
  
• AdC Competition Policy Award, 2020.
  
• IIOC Robert F. Lanzillotti Prize (for Best Paper in Antitrust Economics), 2020.
  
• London Business School Junior Faculty Research Award, 2020.